Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review
JCO Precision Oncology · 2023-08 · (7)
DOI: 10.1200/po.23.00182 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JCO Precision Oncology, 2023-08. Verfasst von Sakti Chakrabarti und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Seidman Cancer Center, Cleveland, OH. Hauptthemen laut MEDLINE: DNA Mismatch Repair, Colorectal Neoplasms, Immunotherapy, Neoadjuvant Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 74 Literaturangaben.
Abstract (Originalsprache)
PURPOSE We conducted a systematic review to evaluate the outcome of patients with early-stage (stages I-III) mismatch repair deficient (dMMR) colorectal cancer (CRC) receiving neoadjuvant immunotherapy (NIT) with immune checkpoint inhibitor (ICI)–based regimens. METHODS MEDLINE, Scopus, Embase, Web of Science, and Cochrane Central Register of Controlled Trials were searched for publications reporting the outcome of patients with early-stage dMMR CRC receiving NIT. The primary outcome measures were the complete response (CR) rate (clinical CR [cCR] or pathologic CR [pCR]) and the incidence of grade 3 or higher toxicities. RESULTS The search identified 37 publications that included 423 patients with colon (n = 326, 77%) and rectal (n = 97,23%) cancers aged 19-82 years; most patients had stage III CRC (88%). Approximately 67% of patients received monotherapy with anti–PD-1 agents; the rest received dual ICIs (ipilimumab plus nivolumab). The CR rate (pCR + cCR) in the overall population was 72% (305 of 423). The R0 resection and pCR rates were 99.3% and 70% among the patients undergoing surgery, respectively. Only four (0.9%) patients had primary resistance to NIT. After median follow-up periods ranging from 4 to 27 months, 3 (0.7%) patients progressed after an initial response. Grade 3 or higher toxicities were uncommon (6.3%), rarely delaying planned surgery. CONCLUSION NIT in patients with early-stage dMMR CRC is associated with a high response rate, low primary resistance to immunotherapy and cancer recurrence rate, and an excellent safety profile. The findings of the present systematic review support further investigation of NIT in patients with early-stage dMMR CRC, with a particular emphasis on the organ-preserving potential of this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University Hospital Seidman Cancer Center, Cleveland, OH.
- University of Iowa Hospitals and Clinics, Iowa City, IA.
- Massachusetts General Hospital Cancer Center, Boston, MA.
- Mayo Clinic, Phoenix, AZ.
ORCID-Profile: Sakti Chakrabarti, Udhayvir Singh Grewal, Kruti Bhagirath Vora, Aparna Raj Parikh, Amit Mahipal, Mohamad Bassam B Sonbol
Zitieren
APA
Chakrabarti, S., Grewal, U. S., Vora, K. B., Parikh, A. R., Almader-Douglas, D., Mahipal, A., & Sonbol, M. B. B. (2023). Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review. JCO Precision Oncology. https://doi.org/10.1200/po.23.00182
Vancouver
Chakrabarti S, Grewal US, Vora KB, Parikh AR, Almader-Douglas D, Mahipal A, et al. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review. JCO Precision Oncology. 2023. doi:10.1200/po.23.00182
BibTeX
@article{Chakrabarti2023,
author = {Chakrabarti, Sakti and Grewal, Udhayvir Singh and Vora, Kruti Bhagirath and Parikh, Aparna Raj and Almader-Douglas, Diana and Mahipal, Amit and Sonbol, Mohamad Bassam B},
title = {Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.23.00182}
}
EUVIMED